TABLE 3.
Group | Age | n | Onset | Duration | Age | FTD-Tau* | Braak Stage† (%) | CERAD Plaques (%) | Thal Phase (%) | LB (%) | TDP-43 (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
CBD | All | 45 | 62.0 | 5.6 | 67.3 | 91.8 | 51 | 33 | 42 | 9 | 33 |
70− | 27 | 55.4 | 5.3 | 61.0 | 89.7 | 33 | 19 | 30 | 4 | 30 | |
70+ | 18 | 70.7 | 6.1 | 76.8 | 94.9 | 78 | 56 | 61 | 17 | 39 | |
PSP | All | 108 | 68.3 | 7.1 | 75.5 | 68.1 | 74 | 41 | 63 | 15 | 14 |
70− | 21 | 60.2 | 5.2 | 65.4 | 70.2 | 35 | 24 | 43 | 24 | 0 | |
70+ | 56 | 67.2 | 7.5 | 74.6 | 70.2 | 77 | 38 | 68 | 11 | 9 | |
80+ | 31 | 76.0 | 7.7 | 84.0 | 62.7 | 94 | 58 | 68 | 16 | 32 |
By PHF1 immunohistochemistry.
By GT-38 immunohistochemistry.